文献速递肿瘤 PET/CT骨显像与常规 SPECT

全身弥散加权MRI与2-[18F]FDG PET在儿童朗格汉斯细胞组织细胞增生症分期与治疗监测中的比较

Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-31

该研究纳入23例儿童朗格汉斯细胞组织细胞增生症(LCH)患儿,基线时行2-[18F]FDG PET与全身弥散加权MRI(WB DW-MRI),其中16例在随访时重复检查。以PET为参考标准,WB DW-MRI诊断肿瘤的敏感度为95.5%、特异度为100%;化疗应答者与无应答者之间SUVratio和ADCmean的治疗前后变化有显著差异。作者认为WB DW-MRI分期与治疗监测的准确性与PET相似,可考虑作为无辐射暴露的替代方法。

要点

  • WB DW-MRI对儿童LCH肿瘤检测的敏感度为95.5%、特异度为100%,与2-[18F]FDG PET相似。
  • 化疗应答者与无应答者之间SUVratio和ADCmean的治疗前后变化有显著差异(p=0.0006和p=0.003)。
  • 作者认为WB DW-MRI可考虑作为无辐射暴露的替代方法,两种方法联合可能优于任一单独方法。

核心结论

  • WB DW-MRI在儿童LCH分期和治疗监测中的准确性与2-[18F]FDG PET相似。
  • 2-[18F]FDG PET仍是评估代谢活跃疾病的获批放射学检查,WB DW-MRI可考虑作为无辐射暴露的替代方法。
  • 两种方法联合可能优于任一单独方法。

研究设计与样本

  • 23例LCH患儿在基线时行2-[18F]FDG PET和WB DW-MRI,由2名核医学医师和2名放射科医师独立评估8个解剖区域有无肿瘤。
  • 16例患儿在随访时也行了2-[18F]FDG PET和WB DW-MRI,由1名放射科医师和1名核医学医师复核随访扫描,收集所有可检测病灶治疗前后肿瘤ADC和SUV的变化。
  • 以2-[18F]FDG PET结果作为肿瘤检测和治疗反应评估的参考标准,治疗反应按Lugano标准评估。

主要发现

  • 基线WB DW-MRI的敏感度为95.5%、特异度为100%(以2-[18F]FDG PET为参考标准)。
  • 2-[18F]FDG PET图像除脊柱和颈部外所有分析区域阅片者间一致性完美(kappa系数=1),脊柱和颈部kappa系数分别为0.89和0.83。
  • WB DW-MRI图像腹部和骨盆阅片者间kappa系数分别为0.65和0.88。
  • 所有病灶治疗前后SUVratio与ADCmean变化呈负相关(r=-0.27,p=0.06)。
  • 化疗应答者与无应答者之间SUVratio和ADCmean的治疗前后变化有显著差异(p=0.0006和p=0.003)。

关键数值与推荐

  • WB DW-MRI诊断肿瘤的敏感度为95.5%,特异度为100%,95%CI采用Clopper-Pearson精确法估计。
  • 化疗应答者与无应答者之间SUVratio变化p=0.0006,ADCmean变化p=0.003。
  • 所有病灶SUVratio与ADCmean治疗前后变化负相关r=-0.27,p=0.06。
  • 2-[18F]FDG PET阅片者间kappa系数:脊柱0.89、颈部0.83,其余区域为1。
  • WB DW-MRI阅片者间kappa系数:腹部0.65、骨盆0.88。

临床怎么用

  • 作者认为WB DW-MRI可考虑作为无辐射暴露的替代方法用于儿童LCH分期和治疗监测。
  • 作者指出2-[18F]FDG PET仍是评估代谢活跃疾病的获批放射学检查。
  • 作者认为两种方法联合可能优于任一单独方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess and compare the diagnostic accuracy of whole-body (WB) DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis (LCH). METHODS: Twenty-three children with LCH underwent 2-[18F]FDG PET and WB DW-MRI at baseline. Two nuclear medicine physicians and two radiologists independently assessed presence/absence of tumors in 8 anatomical areas. Sixteen children also performed 2-[18F]FDG PET and WB DW-MRI at follow-up. One radiologist and one nuclear medicine physician revised follow-up scans and collected changes in tumor apparent diffusion (ADC) and standardized uptake values (SUV) before and after therapy in all detectable lesions. 2-[18F]FDG PET results were considered the standard of reference for tumor detection and evaluation of treatment response according to Lugano criteria. Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of WB DW-MRI at baseline were calculated, and the 95% confidence intervals were estimated by using the Clopper-Pearson (exact) method; changes in tumor SUVs and ADC were compared using a Mann-Whitney U test. Agreement between reviewers was assessed with a Cohen's weighted kappa coefficient. Analyses were conducted using SAS software version 9.4. RESULTS: Agreement between reviewers was perfect (kappa coefficient = 1) for all analyzed regions but spine and neck (kappa coefficient = 0.89 and 0.83, respectively) for 2-[18F]FDG PET images, and abdomen and pelvis (kappa coefficient = 0.65 and 0.88, respectively) for WB DW-MRI. Sensitivity and specificity were 95.5% and 100% for WB DW-MRI compared to 2-[18F]FDG PET. Pre to post-treatment changes in SUVratio and ADCmean were inversely correlated for all lesions (r: -0.27, p = 0·06) and significantly different between responders and non-responders to chemotherapy (p = 0.0006 and p = 0·003 for SUVratio and ADCmean, respectively). CONCLUSION: Our study showed that WB DW-MRI has similar accuracy to 2-[18F]FDG PET for staging and treatment monitoring of LCH in children. While 2-[18F]FDG PET remains an approved radiological examination for assessing metabolically active disease, WB DW-MRI could be considered as an alternative approach without radiation exposure. The combination of both modalities might have advantages over either approach alone.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Baratto L, Nyalakonda R, Theruvath AJ, et al. Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging. 2023. PMID: 36717409. doi:10.1007/s00259-023-06122-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。